Novartis reported positive Phase 3 results for ianalumab in Sjögren’s disease, with the 300 mg monthly subcutaneous regimen meeting the primary endpoint of ESSDAI improvement at week 48 in both NEPTUNUS-1 and NEPTUNUS-2. Numerical benefits emerged by week 16 and were sustained through one year, and safety was comparable to placebo. The company plans global submissions in early 2026, positioning ianalumab to become the first targeted therapy for this heterogeneous autoimmune condition if approved.
The headline is clear: a long-unmet field may finally have a disease-modifying option. The strategic question is whether a regulator-acceptable gain in disease activity will translate into payer-acceptable, patient-perceivable benefit. While physician and patient global assessments trended favorably and some nominal significance appeared in pooled analyses, key patient-reported outcomes on dryness, pain, and fatigue did not reach statistical significance. That gap places an onus on Medical and Market Access teams to connect ESSDAI reductions to outcomes that matter to patients and budgets.
This matters now because Sjögren’s represents a sizable and undertreated population, with systemic involvement in up to 40% of patients and elevated lymphoma risk. Rheumatologists have relied on immunosuppression, off-label B-cell depletion, and symptomatic care, none of which are approved specifically for Sjögren’s. A monthly, subcutaneous, BAFF-R–targeting antibody that both depletes B cells and blocks their activation could reset the standard, particularly in patients with active extraglandular disease—the population studied in NEPTUNUS. For clinicians, a clearer treat-to-target path anchored on disease activity becomes possible. For patients, the promise is control of systemic disease; however, expectations around symptom relief must be carefully managed. For payers, the evidence discussion will hinge on bridging validated disease activity metrics to real-world reductions in flares, steroid exposure, health resource use, and longer-term risks such as lymphoma.
Commercially, the signal shapes a segmentation-first launch. The strongest value proposition sits with systemic, extraglandular disease and potentially biomarker-enriched subsets if post hoc analyses identify responders. The inclusion of an every-three-months arm that was not highlighted as meeting the primary endpoint suggests the registrational dose will likely be monthly, trading convenience for efficacy. That has implications for adherence modeling, home administration services, and pricing relative to other rheumatology biologics. With roughly half of cases estimated undiagnosed, market development will be as critical as share capture—requiring investment in diagnostic pathways, ESSDAI scoring proficiency, and multidisciplinary referral networks.
Strategically, ianalumab reinforces a broader industry pivot back to B-cell biology across autoimmune indications. The BAFF/BAFF-R axis, validated in lupus, is reemerging as a fertile target after mixed results from earlier agents and trial designs in Sjögren’s. Novartis is also evaluating ianalumab across multiple B-cell–driven diseases, signaling a platform ambition. Competitors exploring BAFF/APRIL or B-cell depletion mechanisms will see Sjögren’s as the next contested frontier, particularly if biomarker-driven subgroups deliver clearer benefit.
The next 12–18 months will be defined by evidence translation. To secure regulatory and payer traction, Novartis will need to pair the Phase 3 activity signal with pragmatic, real-world data that show symptom relief, reduced corticosteroid reliance, and downstream cost offsets, while clarifying long-term safety in an extension program. If that bridge is built, Sjögren’s could move from symptomatic management to targeted control. If not, the field risks another near-miss where a statistically positive endpoint fails to reshape clinical practice. The decisive factor will be whether disease activity reductions can be credibly tied to outcomes that patients feel and payers will fund.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
